Generics for Forxiga will be released simultaneously on the

Newly benefits for 89 single and 60 combination drugs

Introduced Dapagliflozin 5mg for the first time

70% of the original prodrug and salt-altered product is the highest price

Chong Kun Dang, Hanmi, Donga ST, Jeil, Boryeong, Daewon, etc.

 

new products launched As generics of the SGLT-2 diabetes treatment drug Forxiga (Dapagliflozin, AstraZeneca) were released simultaneously on the 8th, the related market is expected to intensify.

 

Last year, outpatient prescription sales of Xigduo, a single drug combining Forxiga and Metformin, were 91.4 billion won (Forxiga's sales were 48.5 billion won, Xigduo's sales were 42.9 billion won), and a large market is forming.

 

From the 8th, a total of 149 items (89 single drugs, 60 complex drugs) of Dapagliflozin will be covered by insurance, and fierce competition will unfold for the 90 billion won market.

 

According to the industry on the 5th, the Ministry of Health and Welfare announced that 149 dapagliflozin diabetes treatment drugs would be added to the benefits list from the 8th.

 

Including the two items of Dong-A ST Dapapro, which were on the existing list, a total of 151 Dapagliflozin active ingredient drugs are covered by health insurance.

 

As the market size is large, generics include many large companies.

 

Chong Kun Dang, Hanmi Pharm, Jeil Pharm, Boryung, and Daewon Pharm, which introduced salt-altering drugs, including Dong-A ST, which entered the market first through prodrugs last December, will enter the market.

 

As Forxiga is the first original drug in the SGLT-2 series whose patent has expired, and Daewoong Pharmaceutical, which owns Envlo, is the only domestic company that owns SGLT-2, it is analyzed that large companies have also participated en masse in the generics market.

 

The drugs entering the market this time include 5mg and 10mg of single active ingredients of Dapagliflozin, Metformin 1000mg + Dapagliflozin 10mg, Metformin 500mg + Dapagliflozin 10mg, Metformin 500mg + Dapagliflozin 5mg, and Metformin 1000mg + Dapagliflozin 5mg.

 

Dapagliflozin 5mg is a drug for which the original drug is also registered for reimbursement.

 

Therefore, it is expected that the effect of increasing the market size will be large with the introduction of generics.

 

The upper limit is 262 to 342 won for Dapagliflozin 5mg and 334 to 514 won for 10mg.

 

The highest price of Dapagliflozin 5mg is Dong-A ST Dapapro 5mg.

 

The highest price of 10mg includes Dong-A ST Dapapro 10mg, Hanmi Pharmaceutical Dapalon 10mg, Boryung Trudapa 10mg, Kyungdong Pharmaceutical Dapazin 10mg, Sinil Foxigly 10mg, Han Wha Posilozin 10mg, KUKJE PHARM Focidi 10mg, Daewon Dapaone 10mg, etc.

 

The most expensive drugs are prodrugs or salt-altering drugs, priced at 70% of the original upper limit.

 

On April 8 next year, the additional price will end, and the drug prices will all be the same at 53.55% of the highest price.

 

In the case of a single agent, 5mg is 262 won, and 10mg is 393 won.

 

An official from the pharmaceutical industry explained, "As Forxiga accounts for a large portion of the diabetes treatment market, and since the combination of SGLT-2 drugs has been expanded since April, expectations for generics are also high."